Bayer's Vitrakvi On Track To Become EU’s First Tumor-Agnostic Cancer Treatment

Five new medicines, including what could become Europe’s first ever tumor-agnostic cancer treatment, have been recommended for approval by the European Medicines Agency.

Larotrectinib
Vitrakvi Is First Tumor-Agnostic Treatment Recommended For Pan-EU Approval • Source: Shutterstock

More from Europe

More from Geography